Renal denervation (RDN), as a novel nonpharmacologic intervention for hypertension [1], is considered to be capable of lowing blood pressure through inhibiting sympathetic nervous system (SNS) and renin-angiotensin-aldosterone system (RAAS) hyperactivity [2, 3]. This evidence concerns the gene REN and hypertensive disorder.